Surmodics Profit Margin 2006-2018 | SRDX
Current and historical gross margin, operating margin and net profit margin for Surmodics (SRDX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Surmodics net profit margin as of December 31, 2018 is -1.84%.
|Surmodics Annual Profit Margins
|Surmodics Quarterly Profit Margins
||Medical Products Manufacturing
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.